Pepgen

PepgenMay 31, 2023 · PepGen is developing an oligonucleotide-based therapy that’s meant to address the underlying genetic defect in patients with DM1. The progressive condition affects an estimated 40,000 people in the U.S. and causes a variety of mental and physical disabilities and, often, an early death. PepGen’s plan to get a second oligonucleotide therapy into the clinic has hit a regulatory roadblock courtesy of a clinical hold notice from the FDA.Sep 28, 2022 · PepGen Reports Positive Data from Phase 1 Trial of PGN-EDO51 for the Treatment of Duchenne Muscular Dystrophy. September 28, 2022. PDF Version. - PGN-EDO51 exhibited the highest levels of oligonucleotide delivery and exon skipping in a clinical study following a single dose when compared to publicly available clinical data for other exon 51 ... Jun 1, 2023 · The U.S. Food and Drug Administration ordered PepGen Inc. (Nasdaq: PEPG) not to proceed with a Phase 1 trial of its drug for Myotonic Dystrophy Type 1. The hold is temporary; the agency is... May 11, 2023 · BOSTON, May 11, 2023 (GLOBE NEWSWIRE) -- PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of... May 30, 2023 · May 30, 202321:30 UTC P PEPG NQ1! PepGen P PEPG on Tuesday said its investigational new drug NQ1! application to treat a type of muscle wasting disease had been put on a clinical hold by the U.S. Food and Drug Administration (FDA). PEPG stock slumped 18.4% to $12.88 after hours. PepGen is advancing the development of two parallel phase II studies of PGN-EDO51 — CONNECT1-EDO51 and CONNECT2-EDO51. The company recently received a no objection letter from Health Canada for...PepGen is developing an oligonucleotide-based therapy that’s meant to address the underlying genetic defect in patients with DM1. The progressive condition affects an estimated 40,000 people in the U.S. and causes a variety of mental and physical disabilities and, often, an early death.PepGen Inc. is a clinical-stage biotechnology company advancing the next-generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and ...BOSTON, May 30, 2023 (GLOBE NEWSWIRE) -- PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of...PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today reported financial results for the fourth quarter and full year ended December 31, 2022 and highlighted …May 31, 2023 · Additional risks concerning PepGen’s programs and operations are described in our most recent annual report on Form 10-K on file with the SEC and quarterly report on Form 10-Q that are filed with the SEC. PepGen explicitly disclaims any obligation to update any forward-looking statements except to the extent required by law. Investor Contact The FDA imposed a clinical hold on PepGen’s IND for a drug for myotonic dystrophy type 1 (DM1), slowing down the company’s plans to bring a second …May 31, 2023 · According to PepGen, PGN-EDODM1 can fix more than 60% of mis-splicing events in a murine model of DM1, completely reversing myotonia, the muscle stiffness effect of the disease. The correction was sustained through 24 weeks following a single dose of the therapeutic oligonucleotide. May 30, 2023 · May 30, 202321:30 UTC P PEPG NQ1! PepGen P PEPG on Tuesday said its investigational new drug NQ1! application to treat a type of muscle wasting disease had been put on a clinical hold by the U.S. Food and Drug Administration (FDA). PEPG stock slumped 18.4% to $12.88 after hours. May 31, 2023 · According to PepGen, PGN-EDODM1 can fix more than 60% of mis-splicing events in a murine model of DM1, completely reversing myotonia, the muscle stiffness effect of the disease. The correction was sustained through 24 weeks following a single dose of the therapeutic oligonucleotide. Newsroom. Latest News; Press Releases. Viewpoint Press Releases Archive; Blog; Events. BIO International Convention – 2023; American Brachytherapy Society (ABS) – 2023May 30, 2023 · PepGen Inc. (Nasdaq: PEPG), a clinical-stag PepGen Inc. logy company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, to neuromuscular and neurological diseases May 31, 2023 · PepGen’s plan to get a second oligonucleotide therapy into the clinic has hit a regulatory roadblock courtesy of a clinical hold notice from the FDA. PepGen Reports Positive Data from Phase 1 Trial of PGN-EDO51 for the Treatment of Duchenne Muscular Dystrophy. September 28, 2022. PDF Version. - PGN-EDO51 exhibited the highest levels of oligonucleotide delivery and exon skipping in a clinical study following a single dose when compared to publicly available clinical data for other exon 51 ...PepGen’s Enhanced Delivery Oligonucleotide, or EDO, platform is founded on over a decade of research and development and leverages cell-penetrating peptides …BOSTON, March 13, 2023 (GLOBE NEWSWIRE) -- PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide …May 4, 2023 · BOSTON, May 04, 2023 (GLOBE NEWSWIRE) -- PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of... BOSTON, May 30, 2023 (GLOBE NEWSWIRE) -- PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced that the Company received …PepGen’s plan to get a second oligonucleotide therapy into the clinic has hit a regulatory roadblock courtesy of a clinical hold notice from the FDA.Driven by our proprietary Enhanced Delivery Oligonucleotide (EDO) platform, we are creating a pipeline of disease-modifying therapeutics with the potential to safely and effectively target the root cause of serious genetic diseases, with an initial focus on neuromuscular diseases.According to PepGen, PGN-EDODM1 can fix more than 60% of mis-splicing events in a murine model of DM1, completely reversing myotonia, the muscle stiffness effect of the disease. The correction was sustained through 24 weeks following a single dose of the therapeutic oligonucleotide.PepGen is developing an oligonucleotide-based therapy that’s meant to address the underlying genetic defect in patients with DM1. The progressive condition affects an estimated 40,000 people in the U.S. and causes a variety of mental and physical disabilities and, often, an early death.May 30, 2023 · PepGen Inc. (Nasdaq: PEPG), a clinical-stag PepGen Inc. logy company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, to neuromuscular and neurological diseases PepGen Inc. is a clinical-stage biotechnology company advancing the next-generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and ...According to PepGen, PGN-EDODM1 can fix more than 60% of mis-splicing events in a murine model of DM1, completely reversing myotonia, the muscle stiffness effect of the disease. The correction was sustained through 24 weeks following a single dose of the therapeutic oligonucleotide.The FDA has placed a clinical hold on PepGen ‘s Phase I trial of its neuromuscular candidate, which had been planned for the first half of the year. The Boston biopharma’s stock dropped around 18% post-market Tuesday after the announcement. According to the company, the regulator promised PepGen an official letter within 30 days explaining ...PepGen, the Oxford University spinout company developing therapeutics for Duchenne Muscular Dystrophy (DMD), has raised $108m in its Initial Public Offering (IPO).Jun 20, 2022 · PepGen, Inc., a company advancing next-generation oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, has located 12 of its employees in the ICS, occupying 20 lab benches as well as office and meeting space. Mount Ida Campus of UMass Amherst. According to PepGen, PGN-EDODM1 can fix more than 60% of mis-splicing events in a murine model of DM1, completely reversing myotonia, the muscle stiffness effect of the disease. The correction was sustained through 24 weeks following a single dose of the therapeutic oligonucleotide. marketto
VaxinnatePepGen Inc. is a clinical-stage biotechnology company advancing the next-generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and ...According to PepGen, PGN-EDODM1 can fix more than 60% of mis-splicing events in a murine model of DM1, completely reversing myotonia, the muscle stiffness effect of the disease. The correction was sustained through 24 weeks following a single dose of the therapeutic oligonucleotide.PepGen Inc PEPG filed for mixed shelf of up to $300 million. PepGen shares dropped 3% to $15.66 in the after-hours trading session. Analysts expect JOANN Inc. JOAN to post a quarterly loss at 66 ... backed com
Hii mechanical ticketfairy milford asset May 30, 2023 · BOSTON, May 30, 2023 (GLOBE NEWSWIRE) -- PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of... May 30, 2023 · BOSTON, May 30, 2023 (GLOBE NEWSWIRE) -- PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of... BOSTON, May 04, 2023 (GLOBE NEWSWIRE) -- PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of...
PepgenJun 1, 2023 · The U.S. Food and Drug Administration ordered PepGen Inc. (Nasdaq: PEPG) not to proceed with a Phase 1 trial of its drug for Myotonic Dystrophy Type 1. The hold is temporary; the agency is... Driven by our proprietary Enhanced Delivery Oligonucleotide (EDO) platform, we are creating a pipeline of disease-modifying therapeutics with the potential to safely …BOSTON, May 04, 2023 (GLOBE NEWSWIRE) -- PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of...May 31, 2023 · PepGen is developing an oligonucleotide-based therapy that’s meant to address the underlying genetic defect in patients with DM1. The progressive condition affects an estimated 40,000 people in the U.S. and causes a variety of mental and physical disabilities and, often, an early death. BOSTON, May 30, 2023 (GLOBE NEWSWIRE) -- PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of...May 30, 202321:30 UTC P PEPG NQ1! PepGen P PEPG on Tuesday said its investigational new drug NQ1! application to treat a type of muscle wasting disease had been put on a clinical hold by the U.S. Food and Drug Administration (FDA). PEPG stock slumped 18.4% to $12.88 after hours.Aug 5, 2021 · PepGen was founded by leading neurology researchers in Oxford, UK and is backed by a strong syndicate of investors including RA Capital Management, Oxford Sciences Innovation (OSI), and others ... PepGen is developing an oligonucleotide-based therapy that’s meant to address the underlying genetic defect in patients with DM1. The progressive condition affects an estimated 40,000 people in the U.S. and causes a variety of mental and physical disabilities and, often, an early death.May 30, 2023 · May 30, 202321:30 UTC P PEPG NQ1! PepGen P PEPG on Tuesday said its investigational new drug NQ1! application to treat a type of muscle wasting disease had been put on a clinical hold by the U.S. Food and Drug Administration (FDA). PEPG stock slumped 18.4% to $12.88 after hours. BOSTON, April 06, 2022 (GLOBE NEWSWIRE) -- PepGen, Inc., advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and... velocity risk underwriters etq
Gem capitalMay 31, 2023 · PepGen’s plan to get a second oligonucleotide therapy into the clinic has hit a regulatory roadblock courtesy of a clinical hold notice from the FDA. PepGen P PEPG on Tuesday said its investigational new drug NQ1! application to treat a type of muscle wasting disease had been put on a clinical hold by the U.S. Food and Drug Administration (FDA).; PEPG stock slumped 18.4% to $12.88 after hours. The company's IND was to start an early-stage trial with its investigational …May 31, 2023 · PepGen is developing an oligonucleotide-based therapy that’s meant to address the underlying genetic defect in patients with DM1. The progressive condition affects an estimated 40,000 people in the U.S. and causes a variety of mental and physical disabilities and, often, an early death. May 30, 202321:30 UTC P PEPG NQ1! PepGen P PEPG on Tuesday said its investigational new drug NQ1! application to treat a type of muscle wasting disease had been put on a clinical hold by the U.S. Food and Drug Administration (FDA). PEPG stock slumped 18.4% to $12.88 after hours.Aug 5, 2021 · PepGen Raises $112.5 Million to Advance Transformative Therapies for Neuromuscular Diseases August 5, 2021 PepGen raised $112.5 million in a series B crossover financing round to advance its oligonucleotide platform targeting rare neuromuscular and cardiac diseases, including Duchenne muscular dystrophy. PepGen’s plan to get a second oligonucleotide therapy into the clinic has hit a regulatory roadblock courtesy of a clinical hold notice from the FDA.PepGen Reports Positive Data from Phase 1 Trial of PGN-EDO51 for the Treatment of Duchenne Muscular Dystrophy. September 28, 2022. PDF Version. - PGN-EDO51 exhibited the highest levels of oligonucleotide delivery and exon skipping in a clinical study following a single dose when compared to publicly available clinical data for other exon 51 ...May 31, 2023 · According to PepGen, PGN-EDODM1 can fix more than 60% of mis-splicing events in a murine model of DM1, completely reversing myotonia, the muscle stiffness effect of the disease. The correction was sustained through 24 weeks following a single dose of the therapeutic oligonucleotide. evolution iq
Fanstar seman tov BOSTON, May 30, 2023 (GLOBE NEWSWIRE) -- PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of... BOSTON and OXFORD, England, Feb. 4, 2021 /PRNewswire/ -- PepGen, a biotechnology company focused on transforming the care of patients with neuromuscular diseases through the enhanced delivery of therapeutic oligonucleotides, today announced the appointment of James McArthur, Ph.D., as President and Chief Executive Officer …Mar 31, 2023 · BOSTON, May 11, 2023 (GLOBE NEWSWIRE) -- PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today reported financial results for the first quarter ended March 31, 2023. BOSTON, May 04, 2023 (GLOBE NEWSWIRE) -- PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of...BOSTON, May 11, 2023 (GLOBE NEWSWIRE) -- PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of...PepGen’s plan to get a second oligonucleotide therapy into the clinic has hit a regulatory roadblock courtesy of a clinical hold notice from the FDA.PepGen Inc PEPG filed for mixed shelf of up to $300 million. PepGen shares dropped 3% to $15.66 in the after-hours trading session. Analysts expect JOANN Inc. JOAN to post a quarterly loss at 66 ...
PepgenPepGen’s plan to get a second oligonucleotide therapy into the clinic has hit a regulatory roadblock courtesy of a clinical hold notice from the FDA.BOSTON, March 13, 2023 (GLOBE NEWSWIRE) -- PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide …BOSTON, March 22, 2023 (GLOBE NEWSWIRE) -- PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of...PepGen Inc. is a clinical-stage biotechnology company advancing the next-generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and ... advanced oxy med
WgczPepGen Inc., a clinical-stage biotechnology company, focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases. The company's lead product candidate is PGN-EDO51, an EDO peptide in Phase I clinical trials to treat individuals with Duchenne …May 4, 2023 · BOSTON, May 04, 2023 (GLOBE NEWSWIRE) -- PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of... PepGen is concurrently running a Phase 1 trial of the same drug for Duchenne muscular dystrophy. The company went public in a $108 million IPO last May — one of just eight Massachusetts biotechs ...PepGen Inc. is a clinical-stage biotechnology company advancing the next-generation of oligonucleotide therapies with the goal of transforming the treatment of …PepGen said Tuesday the agency had placed a clinical hold on a planned Phase 1 trial for the treatment, which is being developed for an inherited muscle-wasting condition known as myotonic dystrophy type 1, or DM1. The FDA will detail the reasons for its decision in an official letter within 30 days, PepGen said.May 31, 2023 · PepGen is developing an oligonucleotide-based therapy that’s meant to address the underlying genetic defect in patients with DM1. The progressive condition affects an estimated 40,000 people in the U.S. and causes a variety of mental and physical disabilities and, often, an early death. PepGen is advancing the development of two parallel phase II studies of PGN-EDO51 — CONNECT1-EDO51 and CONNECT2-EDO51. The company recently received a no objection letter from Health Canada for...PepGen Inc. (Nasdaq: PEPG), a clinical-stag PepGen Inc. logy company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, to neuromuscular and neurological diseases mt copeland
Vinods 3power plains marketing PepGen is developing an oligonucleotide-based therapy that’s meant to address the underlying genetic defect in patients with DM1. The progressive condition affects an estimated 40,000 people in the U.S. and causes a variety of mental and physical disabilities and, often, an early death.BOSTON, Nov. 10, 2022 (GLOBE NEWSWIRE) -- PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of …PepGen is concurrently running a Phase 1 trial of the same drug for Duchenne muscular dystrophy. The company went public in a $108 million IPO last May — one of just eight Massachusetts biotechs...May 31, 2023 · PepGen is developing an oligonucleotide-based therapy that’s meant to address the underlying genetic defect in patients with DM1. The progressive condition affects an estimated 40,000 people in the U.S. and causes a variety of mental and physical disabilities and, often, an early death.
PepgenNasdaq PepGen Inc. News Summary PEPG US7133171055 PEPGEN INC. (PEPG) Add to my list Report PepGen Shares Tumble 18.4% After FDA Issues Hold Notice on Study 05/30/2023 | 05:10pm EDT By Paul ZiobroPepGen Inc. (Nasdaq: PEPG), a clinical-stag PepGen Inc. logy company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, to neuromuscular and neurological diseasesMay 31, 2023 · Spun out of Oxford University and backed by RA Capital, PepGen specializes in oligonucleotides — short strands of synthetic RNA or DNA molecules — that it delivers with special cell-penetrating... PepGen said Tuesday the agency had placed a clinical hold on a planned Phase 1 trial for the treatment, which is being developed for an inherited muscle-wasting condition known as myotonic dystrophy type 1, or DM1. The FDA will detail the reasons for its decision in an official letter within 30 days, PepGen said. cummins enterprises kuveyt turk bank
Pipeline angelsPepGen’s plan to get a second oligonucleotide therapy into the clinic has hit a regulatory roadblock courtesy of a clinical hold notice from the FDA.PepGen Inc PEPG filed for mixed shelf of up to $300 million. PepGen shares dropped 3% to $15.66 in the after-hours trading session. Analysts expect JOANN Inc. JOAN to post a quarterly loss at 66 ...BOSTON, May 04, 2023 (GLOBE NEWSWIRE) -- PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of... dyve biosciences
Zepetto grimes auto parts May 4, 2023 · BOSTON, May 04, 2023 (GLOBE NEWSWIRE) -- PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of... BOSTON, March 22, 2023 (GLOBE NEWSWIRE) -- PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of...Jun 1, 2023 · The U.S. Food and Drug Administration ordered PepGen Inc. (Nasdaq: PEPG) not to proceed with a Phase 1 trial of its drug for Myotonic Dystrophy Type 1. The hold is temporary; the agency is... The U.S. Food and Drug Administration ordered PepGen Inc. (Nasdaq: PEPG) not to proceed with a Phase 1 trial of its drug for Myotonic Dystrophy Type 1. The hold is temporary; the agency is...PepGen is developing an oligonucleotide-based therapy that’s meant to address the underlying genetic defect in patients with DM1. The progressive condition …
Checker towingMay 31, 2023 · PepGen’s plan to get a second oligonucleotide therapy into the clinic has hit a regulatory roadblock courtesy of a clinical hold notice from the FDA. May 30, 202321:30 UTC P PEPG NQ1! PepGen P PEPG on Tuesday said its investigational new drug NQ1! application to treat a type of muscle wasting disease had been put on a clinical hold by the U.S. Food and Drug Administration (FDA). PEPG stock slumped 18.4% to $12.88 after hours.Jun 5, 2023 · PepGen Inc PEPG filed for mixed shelf of up to $300 million. PepGen shares dropped 3% to $15.66 in the after-hours trading session. Analysts expect JOANN Inc. JOAN to post a quarterly loss at 66 ... Sep 28, 2022 · PepGen Reports Positive Data from Phase 1 Trial of PGN-EDO51 for the Treatment of Duchenne Muscular Dystrophy. September 28, 2022. PDF Version. - PGN-EDO51 exhibited the highest levels of oligonucleotide delivery and exon skipping in a clinical study following a single dose when compared to publicly available clinical data for other exon 51 ... BOSTON, May 30, 2023 (GLOBE NEWSWIRE) -- PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced that the Company received a clinical hold notice from the U.S. Food a... jp warehouse
Tessolve obsorb Need tax documents for a closed account? Log on above with your old user ID and passwordMay 31, 2023 · PepGen is developing an oligonucleotide-based therapy that’s meant to address the underlying genetic defect in patients with DM1. The progressive condition affects an estimated 40,000 people in the U.S. and causes a variety of mental and physical disabilities and, often, an early death. PepGen is advancing the development of two parallel phase II studies of PGN-EDO51 — CONNECT1-EDO51 and CONNECT2-EDO51. The company recently received a no objection letter from Health Canada for...PepGen Inc PEPG filed for mixed shelf of up to $300 million. PepGen shares dropped 3% to $15.66 in the after-hours trading session. Analysts expect JOANN Inc. JOAN to post a quarterly loss at 66 ...PepGen Inc PEPG filed for mixed shelf of up to $300 million. PepGen shares dropped 3% to $15.66 in the after-hours trading session. Analysts expect JOANN Inc. JOAN to post a quarterly loss at 66 ...
PepgenMay 30, 2023 · BOSTON, May 30, 2023 (GLOBE NEWSWIRE) -- PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of... PepGen is developing an oligonucleotide-based therapy that’s meant to address the underlying genetic defect in patients with DM1. The progressive condition affects an estimated 40,000 people in the U.S. and causes a variety of mental and physical disabilities and, often, an early death.Jun 1, 2023 · The U.S. Food and Drug Administration ordered PepGen Inc. (Nasdaq: PEPG) not to proceed with a Phase 1 trial of its drug for Myotonic Dystrophy Type 1. The hold is temporary; the agency is... BOSTON, May 04, 2023 (GLOBE NEWSWIRE) -- PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of...Jun 20, 2022 · PepGen, Inc., a company advancing next-generation oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, has located 12 of its employees in the ICS, occupying 20 lab benches as well as office and meeting space. Mount Ida Campus of UMass Amherst. BOSTON, May 30, 2023 (GLOBE NEWSWIRE) -- PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of...PepGen's stock price closed at $14.67. It is down -14.16% in the last 3 months and up 20.59% in the last 12 months. PepGen saw positive EPS revisions and negative EPS revisions in the last 90 days. See PepGen's stock price’s past reactions to earnings here. According to InvestingPro, PepGen's Financial Health score is "fair …PepGen’s plan to get a second oligonucleotide therapy into the clinic has hit a regulatory roadblock courtesy of a clinical hold notice from the FDA.BOSTON, May 30, 2023 (GLOBE NEWSWIRE) -- PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of...According to PepGen, PGN-EDODM1 can fix more than 60% of mis-splicing events in a murine model of DM1, completely reversing myotonia, the muscle stiffness effect of the disease. The correction was sustained through 24 weeks following a single dose of the therapeutic oligonucleotide. interswitch banco columbia michelle draper xxi xxi xxi barrett enterprises group kansas fair plan overtune a to z tire farmington nm